Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

KIT-dependent and -independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1/2 inhibition as salvage strategy.

Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Mariño-Enríquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S.

Mol Cancer Ther. 2019 Jul 15. pii: molcanther.1224.2018. doi: 10.1158/1535-7163.MCT-18-1224. [Epub ahead of print]

PMID:
31308077
2.

Transcriptome profiling of adipose tissue reveals depot-specific metabolic alterations among colorectal cancer patients.

Haffa M, Lin T, Holowatyj AN, Kratz M, Toth R, Benner A, Gigic B, Habermann N, Schrotz-King P, Böhm J, Brenner H, Schneider M, Ulrich A, Herpel E, Schirmacher P, Straub BK, Nattenmüller J, Kauczor HU, Ball CR, Ulrich CM, Glimm H, Scherer D.

J Clin Endocrinol Metab. 2019 Jun 21. pii: jc.2019-00461. doi: 10.1210/jc.2019-00461. [Epub ahead of print]

PMID:
31225875
3.

TelomereHunter - in silico estimation of telomere content and composition from cancer genomes.

Feuerbach L, Sieverling L, Deeg KI, Ginsbach P, Hutter B, Buchhalter I, Northcott PA, Mughal SS, Chudasama P, Glimm H, Scholl C, Lichter P, Fröhling S, Pfister SM, Jones DTW, Rippe K, Brors B.

BMC Bioinformatics. 2019 May 28;20(1):272. doi: 10.1186/s12859-019-2851-0.

4.

Variant classification in precision oncology.

Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Fröhlich M, Uhrig S, Kazdal D, Allgäuer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitei N, Bonzheim I, Marienfeld R, Möller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Fröhling S, Stenzinger A.

Int J Cancer. 2019 Apr 22. doi: 10.1002/ijc.32358. [Epub ahead of print]

PMID:
31008532
5.

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.

Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S.

Nat Commun. 2019 Apr 9;10(1):1635. doi: 10.1038/s41467-019-09633-9.

6.

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.

Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003657. doi: 10.1101/mcs.a003657. Print 2019 Apr.

7.

Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model.

Klose J, Trefz S, Wagner T, Steffen L, Preißendörfer Charrier A, Radhakrishnan P, Volz C, Schmidt T, Ulrich A, Dieter SM, Ball C, Glimm H, Schneider M.

PLoS One. 2019 Feb 14;14(2):e0211916. doi: 10.1371/journal.pone.0211916. eCollection 2019.

8.

Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer.

Ehrenberg KR, Gao J, Oppel F, Frank S, Kang N, Dieter SM, Herbst F, Möhrmann L, Dubash TD, Schulz ER, Strakerjahn H, Giessler KM, Weber S, Oberlack A, Rief EM, Strobel O, Bergmann F, Lasitschka F, Weitz J, Glimm H, Ball CR.

Cells. 2019 Feb 10;8(2). pii: E142. doi: 10.3390/cells8020142.

9.

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.

Endris V, Buchhalter I, Allgäuer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Penzel R, Weichert W, Glimm H, Fröhling S, Winter H, Herth F, Thomas M, Schirmacher P, Budczies J, Stenzinger A.

Int J Cancer. 2019 May 1;144(9):2303-2312. doi: 10.1002/ijc.32002. Epub 2019 Feb 4.

PMID:
30446996
10.

Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs.

Wünsche P, Eckert ESP, Holland-Letz T, Paruzynski A, Hotz-Wagenblatt A, Fronza R, Rath T, Gil-Farina I, Schmidt M, von Kalle C, Klein C, Ball CR, Herbst F, Glimm H.

Cell Stem Cell. 2018 Jul 5;23(1):132-146.e9. doi: 10.1016/j.stem.2018.06.003.

11.

Cell-of-Origin DNA Methylation Signatures Are Maintained during Colorectal Carcinogenesis.

Bormann F, Rodríguez-Paredes M, Lasitschka F, Edelmann D, Musch T, Benner A, Bergman Y, Dieter SM, Ball CR, Glimm H, Linhart HG, Lyko F.

Cell Rep. 2018 Jun 12;23(11):3407-3418. doi: 10.1016/j.celrep.2018.05.045.

12.

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H.

Cancer Discov. 2018 Sep;8(9):1087-1095. doi: 10.1158/2159-8290.CD-18-0036. Epub 2018 May 25.

PMID:
29802158
13.

Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma.

Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T.

Eur J Haematol. 2018 Jul;101(1):115-118. doi: 10.1111/ejh.13072. Epub 2018 May 11.

PMID:
29624748
14.

From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.

Perera-Bel J, Hutter B, Heining C, Bleckmann A, Fröhlich M, Fröhling S, Glimm H, Brors B, Beißbarth T.

Genome Med. 2018 Mar 15;10(1):18. doi: 10.1186/s13073-018-0529-2.

15.

Integrative genomic and transcriptomic analysis of leiomyosarcoma.

Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S.

Nat Commun. 2018 Jan 10;9(1):144. doi: 10.1038/s41467-017-02602-0.

16.

Stk33 is required for spermatid differentiation and male fertility in mice.

Martins LR, Bung RK, Koch S, Richter K, Schwarzmüller L, Terhardt D, Kurtulmus B, Niehrs C, Rouhi A, Lohmann I, Pereira G, Fröhling S, Glimm H, Scholl C.

Dev Biol. 2018 Jan 1;433(1):84-93. doi: 10.1016/j.ydbio.2017.11.007. Epub 2017 Nov 16.

17.

Genomics of Immunotherapy-Associated Hyperprogressors-Letter.

Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T.

Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. No abstract available.

18.

Hepatitis B virus surface proteins accelerate cholestatic injury and tumor progression in Abcb4-knockout mice.

Zahner D, Glimm H, Matono T, Churin Y, Herebian D, Mayatepek E, Köhler K, Gattenlöhner S, Stinn A, Tschuschner A, Roderfeld M, Roeb E.

Oncotarget. 2017 Feb 2;8(32):52560-52570. doi: 10.18632/oncotarget.15003. eCollection 2017 Aug 8.

19.

[Personalized oncology].

Heining C, Horak P, Gröschel S, Glimm H, Fröhling S.

Radiologe. 2017 Oct;57(10):804-811. doi: 10.1007/s00117-017-0297-9. Review. German.

PMID:
28875369
20.

Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer.

Cosenza MR, Cazzola A, Rossberg A, Schieber NL, Konotop G, Bausch E, Slynko A, Holland-Letz T, Raab MS, Dubash T, Glimm H, Poppelreuther S, Herold-Mende C, Schwab Y, Krämer A.

Cell Rep. 2017 Aug 22;20(8):1906-1920. doi: 10.1016/j.celrep.2017.08.005.

21.

Precision oncology based on omics data: The NCT Heidelberg experience.

Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S.

Int J Cancer. 2017 Sep 1;141(5):877-886. doi: 10.1002/ijc.30828. Epub 2017 Jun 21.

22.

Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer.

Giessler KM, Kleinheinz K, Huebschmann D, Balasubramanian GP, Dubash TD, Dieter SM, Siegl C, Herbst F, Weber S, Hoffmann CM, Fronza R, Buchhalter I, Paramasivam N, Eils R, Schmidt M, von Kalle C, Schneider M, Ulrich A, Scholl C, Fröhling S, Weichert W, Brors B, Schlesner M, Ball CR, Glimm H.

J Exp Med. 2017 Jul 3;214(7):2073-2088. doi: 10.1084/jem.20162017. Epub 2017 Jun 1.

23.

Colorectal cancer-initiating cells caught in the act.

Dieter SM, Glimm H, Ball CR.

EMBO Mol Med. 2017 Jul;9(7):856-858. doi: 10.15252/emmm.201707858. No abstract available.

24.

Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts.

Ball CR, Oppel F, Ehrenberg KR, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, Bergmann F, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, Weichert W, Weitz J, Glimm H.

EMBO Mol Med. 2017 Jul;9(7):918-932. doi: 10.15252/emmm.201607354.

25.

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.

Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A.

Oncoimmunology. 2017 Jan 27;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017.

26.

Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification.

Knipping F, Osborn MJ, Petri K, Tolar J, Glimm H, von Kalle C, Schmidt M, Gabriel R.

Mol Ther Methods Clin Dev. 2017 Feb 12;4:213-224. doi: 10.1016/j.omtm.2017.01.005. eCollection 2017 Mar 17.

27.

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.

Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Höfer T, Trumpp A, Halama N, Hassel JC, Strobel O, Büchler M, Sahin U, Offringa R.

Oncoimmunology. 2016 Oct 7;5(12):e1240859. doi: 10.1080/2162402X.2016.1240859. eCollection 2016.

28.

Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation.

Dieter SM, Giessler KM, Kriegsmann M, Dubash TD, Möhrmann L, Schulz ER, Siegl C, Weber S, Strakerjahn H, Oberlack A, Heger U, Gao J, Hartinger EM, Oppel F, Hoffmann CM, Ha N, Brors B, Lasitschka F, Ulrich A, Strobel O, Schmidt M, von Kalle C, Schneider M, Weichert W, Ehrenberg KR, Glimm H, Ball CR.

Int J Cancer. 2017 Mar 15;140(6):1356-1363. doi: 10.1002/ijc.30561.

29.

Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls.

Horak P, Fröhling S, Glimm H.

ESMO Open. 2016 Nov 18;1(5):e000094. eCollection 2016. Review.

30.

Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.

Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S.

Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180.

31.

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Fan F, Bashari MH, Morelli E, Tonon G, Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L, Sun C, Hu Y, Ball CR, Glimm H, Sattler M, Goldschmidt H, Wagner EF, Tassone P, Jaeger D, Podar K.

Leukemia. 2017 Jul;31(7):1570-1581. doi: 10.1038/leu.2016.358. Epub 2016 Nov 28.

PMID:
27890927
32.

Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking.

Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R, Peifer M, Helland A, Ball CR, Jechlinger M, Sotillo R, Glimm H, Korbel JO.

Nat Genet. 2017 Jan;49(1):65-74. doi: 10.1038/ng.3722. Epub 2016 Nov 21.

33.

Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.

Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S.

Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446.

PMID:
27687311
34.

Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.

Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S.

Clin Cancer Res. 2017 Feb 15;23(4):962-973. doi: 10.1158/1078-0432.CCR-16-0860. Epub 2016 Aug 17.

35.

[Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer].

Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jäger D, Fröhling S, Springfeld C.

Z Gastroenterol. 2016 May;54(5):426-30. doi: 10.1055/s-0042-103498. Epub 2016 May 12. German.

PMID:
27171333
36.

Increased DNA methylation of Dnmt3b targets impairs leukemogenesis.

Schulze I, Rohde C, Scheller-Wendorff M, Bäumer N, Krause A, Herbst F, Riemke P, Hebestreit K, Tschanter P, Lin Q, Linhart H, Godley LA, Glimm H, Dugas M, Wagner W, Berdel WE, Rosenbauer F, Müller-Tidow C.

Blood. 2016 Mar 24;127(12):1575-86. doi: 10.1182/blood-2015-07-655928. Epub 2016 Jan 4.

37.

Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells.

Dubash TD, Hoffmann CM, Oppel F, Giessler KM, Weber S, Dieter SM, Hüllein J, Zenz T, Herbst F, Scholl C, Weichert W, Werft W, Benner A, Schmidt M, Schneider M, Glimm H, Ball CR.

Cancer Lett. 2016 Feb 28;371(2):326-33. doi: 10.1016/j.canlet.2015.11.037. Epub 2015 Dec 8.

PMID:
26679053
38.

Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.

Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S.

Leukemia. 2016 Apr;30(4):937-46. doi: 10.1038/leu.2015.319. Epub 2015 Nov 19.

PMID:
26582644
39.

High-resolution analysis of the human T-cell receptor repertoire.

Ruggiero E, Nicolay JP, Fronza R, Arens A, Paruzynski A, Nowrouzi A, Ürenden G, Lulay C, Schneider S, Goerdt S, Glimm H, Krammer PH, Schmidt M, von Kalle C.

Nat Commun. 2015 Sep 1;6:8081. doi: 10.1038/ncomms9081.

40.

The tRNA methyltransferase Dnmt2 is required for accurate polypeptide synthesis during haematopoiesis.

Tuorto F, Herbst F, Alerasool N, Bender S, Popp O, Federico G, Reitter S, Liebers R, Stoecklin G, Gröne HJ, Dittmar G, Glimm H, Lyko F.

EMBO J. 2015 Sep 14;34(18):2350-62. doi: 10.15252/embj.201591382. Epub 2015 Aug 13.

41.

So rare we need to hunt for them: reframing the ethical debate on incidental findings.

Schuol S, Schickhardt C, Wiemann S, Bartram CR, Tanner K, Eils R, Meder B, Richter D, Glimm H, von Kalle C, Winkler EC.

Genome Med. 2015 Jul 30;7(1):83. doi: 10.1186/s13073-015-0198-3. eCollection 2015.

42.

Recurrent CDKN1B (p27) mutations in hairy cell leukemia.

Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T.

Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11.

43.

High-throughput monitoring of integration site clonality in preclinical and clinical gene therapy studies.

Giordano FA, Appelt JU, Link B, Gerdes S, Lehrer C, Scholz S, Paruzynski A, Roeder I, Wenz F, Glimm H, von Kalle C, Grez M, Schmidt M, Laufs S.

Mol Ther Methods Clin Dev. 2015 Apr 1;2:14061. doi: 10.1038/mtm.2014.61. eCollection 2015.

44.

Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.

Fisser MC, Rommer A, Steinleitner K, Heller G, Herbst F, Wiese M, Glimm H, Sill H, Wieser R.

Mol Carcinog. 2015 Dec;54(12):1815-9. doi: 10.1002/mc.22252. Epub 2014 Dec 9.

PMID:
25491945
45.

Reply to: NGS library preparation may generate artifactual integration sites of AAV vectors.

Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, Petry H, Gaudet D, Schmidt M.

Nat Med. 2014 Jun;20(6):578-9. doi: 10.1038/nm.3584. No abstract available.

PMID:
24901561
46.

Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.

Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, Modlich U, Beier R, Göhring G, Steinemann D, Fronza R, Ball CR, Haemmerle R, Naundorf S, Kühlcke K, Rose M, Fraser C, Mathias L, Ferrari R, Abboud MR, Al-Herz W, Kondratenko I, Maródi L, Glimm H, Schlegelberger B, Schambach A, Albert MH, Schmidt M, von Kalle C, Klein C.

Sci Transl Med. 2014 Mar 12;6(227):227ra33. doi: 10.1126/scitranslmed.3007280.

47.

NDRG1 prognosticates the natural course of disease in WHO grade II glioma.

Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M, Wick W.

J Neurooncol. 2014 Mar;117(1):25-32. doi: 10.1007/s11060-013-1357-2. Epub 2014 Jan 7.

48.

Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells.

Voloshanenko O, Erdmann G, Dubash TD, Augustin I, Metzig M, Moffa G, Hundsrucker C, Kerr G, Sandmann T, Anchang B, Demir K, Boehm C, Leible S, Ball CR, Glimm H, Spang R, Boutros M.

Nat Commun. 2013;4:2610. doi: 10.1038/ncomms3610.

49.

Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.

Jethwa A, Hüllein J, Stolz T, Blume C, Sellner L, Jauch A, Sill M, Kater AP, te Raa GD, Geisler C, van Oers M, Dietrich S, Dreger P, Ho AD, Paruzynski A, Schmidt M, von Kalle C, Glimm H, Zenz T.

Br J Haematol. 2013 Nov;163(4):496-500. doi: 10.1111/bjh.12539. Epub 2013 Aug 27.

PMID:
24032483
50.

A largely random AAV integration profile after LPLD gene therapy.

Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, Petry H, Gaudet D, Schmidt M.

Nat Med. 2013 Jul;19(7):889-91. doi: 10.1038/nm.3230. Epub 2013 Jun 16.

PMID:
23770691

Supplemental Content

Support Center